DJIA 17,730.11 -27.80 -0.16%
NASDAQ 5,009.21 0.00 0.00%
S&P 500 2,076.78 -0.64 -0.03%
market minute promo

Gilead Sciences (NASDAQ: GILD)

company name or ticker
Company Photos
(Click to zoom)

RedHill Biopharma Surges on Encouraging Data on RHB-105 - Analyst Blog

3 Drugs Stocks Pushing Industry Growth

Biotech Bio-Hazard

Weekly CFO Sells Highlight: Comcast Corp, Affiliated Managers Group Inc, and Gilead Sciences Inc.

Agios Reports New Data on Hematologic Malignancy Drugs - Analyst Blog

AstraZeneca Presents Phase III Data on Gout Drug Lesinurad - Analyst Blog

Biotech's Rally Has Long-Term Legs, Asserts S&P Capital IQ Director

iShares U.S. Healthcare ETF Experiences Big Outflow

Gilead Sciences' Next Growth Market

Gilead recently received approval for Sovaldi in Japan. How big of an opportunity is this for the company?

Why I'm Shorting Biotech

Biotech has been crushing the broader markets for several years running at this point. However, this amazing run might be about to come to a screeching halt, making now a good time to short biotech.